drugset / Trial / NCT01674738
TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV
Phase 2
Withdrawn
Aktion Bronchialkarzinom e.V.
Eli Lilly and Company · collabRoche Pharma AG · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study wants to determine the activity of a first-line treatment related to Thymidylate Synthetase (TS) Expression. Patients with the diagnosis of non-squamous advanced Non-Small-Cell Lung-Cancer (Stage IV) and without evidence of EGFR mutation may be enclosed in this clinical trial.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Outcome
Outcome not reported
Stopped (Business): “Decision of the Sponsor, as the funding of the study was no longer guaranteed.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |